effect of dark chocolate consumption on metabolic syndrome

Evaluation of the effect of chocolate consumption on oxidative stress conditions, glucose and lipid profile and insulin resistance in patients with metabolic syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013022812122N2

Enrollment

114

Registered

2013-04-28

Start date

2013-05-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic syndrome. Personal history of endocrine, nutritional and metabolic diseases

Interventions

Intervention 1: intervension group 1= two times Dark chocklate consumption per day, each time 10gr. Intervention 2: control group= recieve no intervension. Intervention 3: intervension group2= 2 times

Treatment - Other

intervension group 1= two times Dark chocklate consumption per day, each time 10gr

control group= recieve no intervension

intervension group2= 2 times dark chocklate per day, each time 20gr

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: diagnosed metabolic syndrome based on NCEP definition by speceialist and age of 30 to 60 years; without any kidney, liver, heart, stomach,thyroid disease, anemia and Fibrocystic breast; not taking vitamin and antioxidant supplements in recent months; not pregnant or lactating. exclusion criteria: taking less than 80% of given chocolates; changing the type and dose of routine medicine.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Oxidative stress condition. Timepoint: Before and after intervention. Method of measurement: measurement of plasma free radical trapping capacity ,and serum MDA.;Fasting Blood Sugar. Timepoint: Before and after intervention. Method of measurement: enzymatic.;Insulin resistance. Timepoint: Before and after intervention. Method of measurement: HOMA calculation.;Serum triglyceride. Timepoint: Before and after intervention. Method of measurement: enzymatic.;Total cholesterol. Timepoint: Before and after intervention. Method of measurement: enzymatic.;High density Lipoprotein (HDL). Timepoint: Before and after intervention. Method of measurement: enzymatic.;Low density Lipoprotein (lDL). Timepoint: Before and after intervention. Method of measurement: freidewald formula.	—

Measure

Time frame

Oxidative stress condition. Timepoint: Before and after intervention. Method of measurement: measurement of plasma free radical trapping capacity ,and serum MDA.;Fasting Blood Sugar. Timepoint: Before and after intervention. Method of measurement: enzymatic.;Insulin resistance. Timepoint: Before and after intervention. Method of measurement: HOMA calculation.;Serum triglyceride. Timepoint: Before and after intervention. Method of measurement: enzymatic.;Total cholesterol. Timepoint: Before and after intervention. Method of measurement: enzymatic.;High density Lipoprotein (HDL). Timepoint: Before and after intervention. Method of measurement: enzymatic.;Low density Lipoprotein (lDL). Timepoint: Before and after intervention. Method of measurement: freidewald formula.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAkram Naghdipour

Yazd Shahid Sadoughi University of Medical Sciences

naghdipour86@yahoo.com+98 35 1623 4120

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026